Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-109	-89.3	-111.57	-166.01	-174.52
Depreciation & Amortization	1.15	1.25	1.37	1.17	0.49
Stock-Based Compensation	13.3	13.1	7.91	18.04	18.18
Other Adjustments	6.83	6.19	47.28	39.89	10.14
Changes in Accounts Payable	-0.15	-2.92	-2.3	-7.8	14.49
Changes in Accrued Expenses	6.29	-1.42	-6.28	-9.32	17.54
Changes in Unearned Revenue	-9.77	-8.33	-15.45	33.56	-
Changes in Other Operating Activities	-1.73	0.21	6.01	2.09	-3.37
Operating Cash Flow	-93.09	-81.23	-73.02	-88.39	-117.04
Capital Expenditures	-0.74	-0.37	-3.87	-20.62	-15.3
Purchases of Intangible Assets	-	-	-3.5	-4.25	-6.25
Other Investing Activities	0.13	0.01	0.02	-0.06	-
Investing Cash Flow	-0.6	-0.36	-7.35	-24.93	-21.55
Long-Term Debt Issued	49.85	-	39.55	-	39.96
Long-Term Debt Repaid	-40.61	-	-43	-	-
Net Long-Term Debt Issued (Repaid)	9.24	-	-3.45	-	39.96
Issuance of Common Stock	265.69	76.87	140.86	53.5	-
Net Common Stock Issued (Repurchased)	265.69	76.87	140.86	53.5	-
Other Financing Activities	-0.34	-0.19	-1.02	-1.4	-0.87
Financing Cash Flow	274.59	76.68	136.39	52.1	39.08
Net Cash Flow	180.9	-4.9	56.02	-61.22	-99.51
Free Cash Flow	-93.83	-81.6	-76.89	-109.01	-132.35
FCF Margin	-960.07%	-979.23%	-497.62%	-4356.87%	-
Free Cash Flow Per Share	-0.29	-0.33	-0.66	-2.48	-3.52
Levered Free Cash Flow	-104.72	-100.89	-135.53	-166.94	-120.71
Unlevered Free Cash Flow	-115.46	-103.06	-92.95	-163.38	-159.41

Updated Mar 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q